Medullary thyroid cancer (MTC) is a rare neuroendocrine malignancy arising from parafollicular C cells. Diagnosis is based on cytologic and histologic features, supported by biochemical testing for calcitonin and carcinoembryonic antigen, RET germline testing, and appropriate imaging. This educational review, developed by the Society of Surgical Oncology's Endocrine and Head and Neck Disease Site Working Group, provides an updated overview of the diagnosis and management of MTC, emphasizing evolving surgical principles and the integration of targeted therapies. Ongoing multidisciplinary collaboration and participation in clinical trials remain essential to further refine prognostic tools, optimize treatment sequencing, and improve patient outcomes in MTC.
Post-stroke dysphagia is associated with increased healthcare costs and resource utilization. This analysis sought to evaluate acute clinical and economic outcomes among patients with stroke, with and without post-stroke dysphagia, and other associated sequelae. A retrospective analysis of Medicare inpatient claims was conducted. The analysis sample included patients with a diagnosis of acute ischemic (AIS) and hemorrhagic (intracerebral hemorrhage, ICH) stroke, with or without subsequent post-stroke complications of dysphagia, pneumonia, and percutaneous endoscopic gastrostomy (PEG) placement. The primary outcomes were total length of stay (LOS) and intensive care unit (ICU), days, costs (derived from charges using cost-to-charge ratios), reimbursement, and discharge destination. Regression analyses explored the relationship between LOS and cost for patients with dysphagia and AIS or ICH. A total of 595,903 patients with AIS or ICH stroke (N = 474,634 AIS and N = 95,020 ICH) were included, with dysphagia (13.0
BACKGROUND:Blood transfusion before arrival at a hospital reduces mortality from traumatic hemorrhage and shock. Whether transfusion with whole blood is more beneficial than transfusion with blood components is uncertain, as are the effects of the length of time that blood products are in storage between donation and transfusion. METHODS:In this pragmatic, multicenter, phase 3, cluster-randomized trial, we assigned 44 air medical bases in a 2:1 ratio to the use of up to 2 units of whole blood or as-indicated blood components (plasma, red cells, or both) for prehospital transfusion in trauma patients during 1-month blocks. The primary outcome was death from any cause within 30 days after randomization. An observational substudy assessed outcomes according to the storage age of whole blood. RESULTS:Of 1020 eligible patients transported to hospitals by the air bases, 715 were assigned to receive whole blood and 305 to receive blood components; 695 and 298, respectively, were included in the primary analysis. Mortality at 30 days was 25.9% in the whole-blood group and 20.5% in the component group (adjusted odds ratio, 1.24; 95% confidence interval [CI], 0.87 to 1.76; P = 0.24). No substantial between-group differences in adverse events were observed. In the observational substudy, 30-day mortality was 27.1% among 210 patients who received whole blood with a storage age of 15 to 21 days and 26.4% among 443 patients who received whole blood with a storage age of 1 to 14 days (adjusted odds ratio, 0.99; 95% CI, 0.74 to 1.32). CONCLUSIONS:In injured patients with hemorrhagic shock, the use of whole blood for prehospital transfusion did not result in lower 30-day mortality than the use of blood components. (Funded by the Defense Health Agency Research Technology Portfolio Management, Combat Casualty Portfolio; TOWAR ClinicalTrials.gov number, NCT04684719.).
BACKGROUND:Dravet syndrome is a severe developmental and epileptic encephalopathy caused primarily by SCN1A haploinsufficiency. Risks of sudden unexpected death in epilepsy and cognitive deficits are higher among patients with this syndrome than in the general population with epilepsy. The effects of zorevunersen, an antisense oligonucleotide designed to up-regulate NaV1.1 sodium channels, in patients with Dravet syndrome are not known. METHODS:We enrolled patients 2 to 18 years of age with Dravet syndrome who were receiving standard antiseizure medications in two phase 1-2a, open-label, multicenter studies (MONARCH and ADMIRAL). Patients were included in either a single-ascending-dose cohort, in which zorevunersen (10 to 70 mg) was administered on day 1 only, or a multiple-ascending-dose cohort, in which zorevunersen (20 to 70 mg) was administered two or three times in a 3-month period. Patients eligible for rollover to the two open-label extension studies (SWALLOWTAIL and LONGWING) continued to receive zorevunersen (≤45 mg) every 4 months. The safety and pharmacokinetics of zorevunersen were assessed in the primary analysis; clinical effects were also evaluated. RESULTS:A total of 81 patients were enrolled in the phase 1-2a studies. As of May 30, 2025, a total of 75 patients had entered the extension studies. Most adverse events were mild or moderate. The most common adverse event was post-lumbar puncture syndrome (in 25% of patients) in the phase 1-2a studies and was an elevated protein level in cerebrospinal fluid (in 45%) in the extension studies. One patient had suspected unexpected serious adverse reactions, 1 had an adverse event that led to study withdrawal, 2 died from sudden unexpected death in epilepsy, and 1 died from malnutrition. Patients who received 70 mg of zorevunersen (one, two, or three doses) in the phase 1-2a studies, followed by up to 45 mg in the extension studies, had a median change from baseline in convulsive-seizure frequency ranging from -58.82% to -90.91% across 1-month intervals during the first 20 months of the extension studies. The data supported improvements in overall clinical status, quality of life, and adaptive behavior with continued treatment for up to 36 months in the extension studies. CONCLUSIONS:The safety profile and initial clinical improvement support the continued development of zorevunersen as a potential disease-modifying treatment for Dravet syndrome. (Supported by Stoke Therapeutics; MONARCH and SWALLOWTAIL ClinicalTrials.gov numbers, NCT04442295 and NCT04740476, respectively; ADMIRAL and LONGWING ISRCTN Registry numbers, ISRCTN99651026 and ISRCTN12811235, respectively.).
For patients experiencing cancer, nurse navigation can ease the burden of complex care by enhancing coordination of health services and patient outcomes. However, in under-resourced areas, trained nurse navigators may be limited or non-existent. In the United States, artificial intelligence (AI)-enabled digital health tools are increasingly available and may help address gaps in care coordination; however, most are not designed to specifically support nursing. This perspective piece discusses a human-centered AI framework that integrates empathic and agentic approaches grounded in the American Nurses Association's code of ethics to support nurses in the United States in cancer care navigation. The framework could augment, not replace, human empathy and agency while improving nurse workflow, patient-clinician relationships, and care coordination services in under-resourced areas.
